Skip to main content

Third Wave, Mitsubishi Form Joint Venture to Develop PGx-Based Diagnostics

NEW YORK, April 6 (GenomeWeb News) - Third Wave Technologies and Mitsubishi have formed a joint venture for personalized medicine in Japan and the Asia-Pacific region, the companies said yesterday.


The joint venture, Third Wave Japan, plans to develop products for the Japanese molecular diagnostic market, including tests for diagnosing infectious diseases and products to improve drug safety and efficacy.


Third Wave will hold worldwide rights outside the Asia-Pacific region to any new technology or product developed by Third Wave Japan.


Third Wave Japan and Mitsubishi also plan to accelerate the penetration of Third Wave's Invader products in clinical laboratories in the region, especially in Japan.


Mitsubishi has a 14-percent minority investment in Third Wave Japan. In addition, CSK Holdings, through its new subsidiary CSK Institute for Sustainability, will hold a 3-percent stake in the joint venture.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.